WithdrawnPhase 1NCT03773328
A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)
Studying Acute inflammatory demyelinating polyradiculoneuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cellenkos, Inc.
- Principal Investigator
- Tara SadeghiSponsor GmbH
- Intervention
- CK0801(biological)
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2022 – 2027
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03773328 on ClinicalTrials.govOther trials for Acute inflammatory demyelinating polyradiculoneuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06822231High-Tech Rehabilitation Pathway for Acute Adult Neuromuscular Diseases - Fit4MedRob-Acute MND ProjectIstituti Clinici Scientifici Maugeri SpA
- ACTIVE NOT RECRUITINGPHASE4NCT06620198Upper Limb Robot-Assisted Therapy in Patients with Guillain-Barré SyndromeI.R.C.C.S. Fondazione Santa Lucia
- RECRUITINGNCT06615622Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrodiagnostic Findings and if This Method Aids Early Diagnosis, Predict Their Outcomes and Differentiate Between Axonal and Demyelinating Subtypes.Assiut University
- RECRUITINGNANCT05461898RehabGBs: Rehabilitation in People With Guillain-Barré SyndromeCentro de Reabilitacao do Norte
See all trials for Acute inflammatory demyelinating polyradiculoneuropathy →